At the time of writing, Nurix Therapeutics Inc [NRIX] stock is trading at $19.55, down -8.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NRIX shares have gain 19.57% over the last week, with a monthly amount glided 58.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Outperform rating on October 21, 2025, and set its price target to $24. On March 17, 2025, Leerink Partners initiated with a Market Perform rating and assigned a price target of $16 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $35 on December 10, 2024. BMO Capital Markets initiated its recommendation with an Outperform and recommended $35 as its price target on December 06, 2024. UBS started tracking with a Buy rating for this stock on October 24, 2024, and assigned it a price target of $35. In a note dated October 11, 2024, Jefferies initiated a Buy rating and provided a target price of $41 on this stock.
For the past year, the stock price of Nurix Therapeutics Inc fluctuated between $8.18 and $22.95. Currently, Wall Street analysts expect the stock to reach $27.44 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $19.55 at the most recent close of the market. An investor can expect a potential return of 40.36% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
According to Nurix Therapeutics Inc [NASDAQ:NRIX], the company’s sales were 83.69M for trailing twelve months, which represents an -37.29% plunge. Gross Profit Margin for this corporation currently stands at -1.63% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.62 points at the first support level, and at 17.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.24, and for the 2nd resistance point, it is at 22.92.
Ratios To Look Out For
It is important to note that Nurix Therapeutics Inc [NASDAQ:NRIX] has a current ratio of 5.35. Also, the Quick Ratio is 5.35, while the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 23.68, the price to book ratio is 4.04.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Nov 24 ’25 when 37600.0 shares were sold. Officer, CHRISTINE RING completed a deal on Nov 24 ’25 to buy 37600.0 shares. Meanwhile, Chief Financial Officer van Houte Hans sold 6284.0 shares on Nov 03 ’25.
